Fusidic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fusidic Acid: Exposure keratitis
One-Sentence Summary
Fusidic acid is an antibiotic used mainly against Gram-positive bacterial infections, particularly Staphylococcus, and its original indications include skin, respiratory and urinary tract infections. The TxGNN model predicts it may be effective for exposure keratitis, with 0 clinical trials and 1 publication (a case series on ocular Tsukamurella infections) linked to this prediction. The evidence is indirect, and the high model score is not backed by clinical data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Exposure keratitis |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Fusidic acid inhibits bacterial elongation factor G, which blocks protein synthesis. It is active mainly against Gram-positive organisms such as Staphylococcus. Detailed mechanism of action data was not available in the data compiled for this report, so this description reflects the drug’s generally known pharmacology.
Exposure keratitis is a surface injury of the cornea caused by incomplete eyelid closure and drying. It can become secondarily infected. A Gram-positive antibacterial could in theory help in that secondary infection, but it would not treat the underlying exposure injury.
The only linked publication is a case series on ophthalmic Tsukamurella infections. This is an indirect and anecdotal connection. The very high TxGNN score is therefore not supported by clinical data, and the prediction should be treated as a hypothesis only.
Other predictions. The model’s other top-ranked predictions are weaker still. Most are non-specific categories (for example, non-human animal disease, post-infectious syndrome, post-bacterial disorder) or conditions where an antibacterial has no clear role (for example, Chagas cardiomyopathy, parasitic eyelid infestation, postinfectious vasculitis, infective urethral stricture and infection-related haemolytic uraemic syndrome). The one biologically plausible alternative is otitis externa, where Staphylococcus aureus (including MRSA) is a common pathogen. It is classed as a research question, with only microbiology and resistance surveys (mostly in dogs) and two human discharging-ear bacteriology studies behind it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case series | Cornea | Largest case series of Tsukamurella-associated ophthalmic infections, including the first report of ocular implant infection after enucleation. It describes clinical spectrum, risk factors, treatment and outcome, but does not show efficacy of fusidic acid for exposure keratitis. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 10782L | Fucidin | Tablet containing sodium fusidate 250 mg (oral) | Not available in the data compiled for this report |
Safety Considerations
The data compiled for this report did not include label warnings, contraindications or drug interaction information (the drug interaction query returned no results).
The knowledge graph links fusidic acid with a number of conditions as possible contraindications. These are not label text and should be verified. Examples include:
- Hepatic and renal: liver failure, liver disease, kidney disease, gallbladder disease
- Metabolic: diabetes mellitus, diabetic ketoacidosis, potassium deficiency, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disorders
- Cardiac: atrial fibrillation, atrioventricular block, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome
- Neuromuscular and respiratory: myasthenia gravis, neuromuscular junction disease, respiratory failure
- Gastrointestinal: Clostridium difficile colitis, colitis, necrotising enterocolitis
- Ocular: glaucoma, ocular hypertension, herpes simplex keratitis, conjunctivitis, eye infections
Several of these ocular entries are relevant to the predicted eye indication and need careful review. Please refer to the TGA-approved Product Information (PI) for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, supported by a single indirect case series and no registered trials. The mechanism may plausibly help with secondary Gram-positive infection, but not with exposure keratitis itself. The Australian product is an oral tablet, which does not match the topical route normally needed for corneal conditions.
To proceed, the following is needed:
- The TGA-approved Product Information, including warnings, contraindications and approved indications, to complete the safety screen
- Confirmed mechanism of action data from DrugBank
- Evidence that fusidic acid benefits exposure keratitis or its secondary infection, such as a case-control study or an early-phase trial
- Assessment of route compatibility, since an ophthalmic formulation would be required and none is listed in the data
- If pursuing otitis externa instead, local Staphylococcus resistance data and human clinical studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.